Browse drugs

…ith poor tolerability and lethality at high doses. In contrast, HM16390 induced a dose-dependent increase in Tregs, which appeared to s…

…vesical co-delivery of doxorubicin (DOX) and the TLR7/8 agonist IMDQ. This nanosystem localizes within the bladder wall and responds…

…pecific T cell responses. When combined with anti-PD-1 therapy, VTX-P04 enhances survival and reduces tumor burden in a preclinical pro…

…vely, these findings establish preclinical proof-of-concept for mRNA-4106, supporting its potential as a broadly applicable, off-the-shel…

…omes, debris). 1 2 By simultaneously engaging CD40 and CEACAM5, ATOR-4066 promotes localized activation of dendritic cells (DCs) and macr…

…also in HCC1954 cells, which are known to exhibit resistance to trastuzumab. In vivo, treatment with trastuzumab-conjugated PTEN LNPs in HC…

…biopsies, infiltrating CD3 + T cells increased after 3 doses of tebentafusp, more so in TCF high patients (3.4 fold change [FC]) compared t…

…itional drugs: the TCR-based Tebentafusp and the antibody-based Tarlatamab. The limited progress in this field is largely attributed to ch…

… This is the first report of anchoring a humanized mAb to alum. ANK-201 was associated with enhanced CD40 signaling in vitro, generatio…

… delays (CD) due to neutropenia in chemotherapy cycles in which pegfilgrastim (PGF) was administered on the same day (D0) vs the following da…

…al remission rates after 5 years were 40.8%, 26.5% and 28.0% on upadacitinib 7.5, 15 and 30 mg, respectively (non-responder imputation).Conc…

…ceiving hormone-modulating medications (including testosterone, somatropin, adrenal cortical steroids, and thyroid hormones) were excluded…